What is 10x Genomics, Inc.'s remainder of fiscal year 2024?

10x Genomics, Inc. (TXG) reported remainder of fiscal year 2024 of $11.55M in Q1 2026.

How has 10x Genomics, Inc.'s remainder of fiscal year 2024 changed year-over-year?

10x Genomics, Inc.'s remainder of fiscal year 2024 increased by 14.4% year-over-year, from $10.1M to $11.55M.

10x Genomics, Inc. TXG Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

IlluminaILMN

——

Twist Bioscience CorporationTWST

——

RevvityRVTY

——

Bio-Rad LaboratoriesBIO

——

Tempus AI, Inc.TEM

——

Agilent TechnologiesA

——

Other financials

Income statement

See full

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

See full

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

See full

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation

See full

Market cap$4.41B+154%

Enterprise value$4B+199%

P/S6.9×+4.1×

Profitability

See full

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

See full

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 10x Genomics, Inc.'s remainder of fiscal year 2024?: 10x Genomics, Inc. (TXG) reported remainder of fiscal year 2024 of $11.55M in Q1 2026.
How has 10x Genomics, Inc.'s remainder of fiscal year 2024 changed year-over-year?: 10x Genomics, Inc.'s remainder of fiscal year 2024 increased by 14.4% year-over-year, from $10.1M to $11.55M.